AAA-603 is under clinical development by Advanced Accelerator Applications and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AAA-603’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AAA-603 overview

AAA-603 is under development for the treatment of multiple solid tumors like gastrointestinal stromal tumors, glioblastoma, metastatic prostate cancer, lung cancer, neuroblastoma, ovarian, head and neck, recurrent glioblastoma multiforme, esophageal and human epidermal growth factor receptor 2 negative breast cancer (her2- breast cancer). The drug candidate is a bombesin analogue radioconjugated radiolabelled with 177Lu. It is based on molecular nuclear therapy that combines two approaches such as tumor targeting and radiation therapy. The drug candidate acts by targeting gastrin releasing peptide receptor (GRPR). It is a new molecular entity. It is administered through intravenous route.

It was under development for the treatment of colorectal cancer.

Advanced Accelerator Applications overview

Advanced Accelerator Applications (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. The company is also involved in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). It’s key brand portfolio comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, Lysakare, Dopaview, Padoview and Lumark. AAA is headquartered in Rueil-Malmaison Cedex, Ile-de-France, France.

For a complete picture of AAA-603’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.